GLPG VS LIVN Stock Comparison

Performance

GLPG
75/100

GLPG returned -9.92% in the last 12 months. Based on SPY's performance of -13.22%, its performance is above average giving it a score of 74 of 100.

LIVN
10/100

LIVN returned -10.04% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

GLPG
78/100

8 analysts offer 12-month price targets for GLPG. Together, they have an average target of 88.89, the most optimistic target put GLPG at 97 within 12-months and the most pessimistic has GLPG at 83.74.

LIVN
64/100

9 analysts offer 12-month price targets for LIVN. Together, they have an average target of 71, the most optimistic target put LIVN at 88 within 12-months and the most pessimistic has LIVN at 62.

Technicals

GLPG
71/100

GLPG receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

LIVN
43/100

LIVN receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

GLPG
10/100

GLPG has missed earnings 10 times in the last 20 quarters.

LIVN
69/100

LIVN has missed earnings 2 times in the last 20 quarters.

Profit

GLPG
40/100

Out of the last 20 quarters, GLPG has had 8 profitable quarters and has increased their profits year over year on 6 of them.

LIVN
37/100

Out of the last 20 quarters, LIVN has had 7 profitable quarters and has increased their profits year over year on 5 of them.

Volatility

GLPG
50/100

GLPG has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

LIVN
47/100

LIVN has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Galapagos NV Summary

Nasdaq / GLPG

Healthcare

Biotechnology

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

LivaNova PLC Ordinary Shares Summary

Nasdaq / LIVN

Healthcare

Medical - Devices

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Power up your portfolio